Non-Executive Directors - Appointment and Resignation
Convatec Group PLC (“Convatec” or “the Company”) is pleased to announce the appointment of Sharon O’Keefe as a Non-Executive Director of the Company with effect from 1 March 2022. Sharon will join Convatec’s Remuneration and Nomination committees on the same date.
The Company also announces that Rick Anderson, Non-Executive director, is stepping down from the Board with effect from 3 March 2022. Rick has made a significant and valuable contribution to Convatec since 2016 for which the Board is immensely grateful. Rick is also Chairman and MD of Revival Healthcare Capital, a role which has recently expanded, and this has led to his reluctant decision to step down from the Board of Convatec.
From 2011 to 2020, Sharon was President and Chief Operating Officer of U Chicago Medicine, a US nationally ranked medical centre with a network of physicians and speciality clinics with 10,000 employees and operating revenue in excess of $2 billion.
Sharon has over 40 years of healthcare and executive experience, with particular focus on quality, efficiency and innovation to create high performance healthcare organisations.
Sharon is a non-executive director of Adtalem Global Education, a $1.1 billion global educational services company and of Vocera Communications, a $200 million healthcare technology company. She was previously a non-executive directors of Aviv REIT, a healthcare real estate investment trust that was acquired by Omega Healthcare Investors in 2015.
Sharon has an M.S. in Nursing Administration from the Loyola University of Chicago, and a B.S. in Nursing from the Northern Illinois University.
John McAdam, Chairman of Convatec, commented:
“I am delighted to welcome Sharon to our Board. She has extensive executive-level experience in medical centre environments with deep insight into patient care quality, engagement and innovation. Sharon brings to the Board very relevant international, medical and patient-focused experience. We look forward to Sharon’s contribution to our Board discussions.”
“The Board is sorry to lose Rick’s valuable contribution to the Board’s discussions and his deep insight into the medical device industry. The Board accepts that Rick is now having to devote more of his time to his role at Revival Healthcare and we wish Rick every success and happiness for the future.”
This announcement is made in accordance with Listing Rule 9.6.11R (1). No other information is required to be disclosed in accordance with Listing Rule 9.6.13.
Analysts and Investors
Kate Postans, Vice President, Investor Relations +44(0)7826 447 807
Buchanan: Chris Lane +44(0)207 466 5000
Convatec Group PLC's LEI code is 213800LS272L4FIDOH92
About Convatec Group PLC
Convatec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion care. Our vision, which encompasses our purpose, is: Pioneering trusted medical solutions to improve the lives we touch. Our products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. To learn more about Convatec, please visit www.convatecgroup.com
Convatec announces the introduction of ConvaFoam™
Convatec announces the introduction of ConvaFoam™Read more
Capital Markets Event
Trading Update for the 10 months ended 31 October 2022
Interim Results for the six months ended 30 June 2022Read more
Entry into the attractive wound biologics segment through the acquisition of Triad Life Sciences IncRead more
Non-Executive Directors - Appointment and ResignationRead more
Annual Results for the twelve months ended 31 December 2021Read more
Convatec Group completes acquisition of Triad Life Sciences Inc as it enters attractive wound biologics segmentRead more
Convatec invests in BlueWind Medical to fund development of innovative neuromodulation technologyRead more
AGM trading update for the four months ended 30 April 2022Read more
Board committee changesRead more